You Won’t Believe How Much $10,000 Invested in Canopy Growth (TSX:WEED) in 2014 Is Worth Today

A $10,000 investment made in Canopy Growth Corp (TSX:WEED)(NYSE:CGC) back in June 2014 would have made an investor pretty wealthy.

| More on:
potted green plant grows up in arrow shape

Image source: Getty Images

It’s no secret shares of Canopy Growth (TSX:WEED)(NYSE:CGC) have done well over the last five years. Everyone knows this.

Canopy has been through a lot of changes over the last half-decade, working towards its stated goal of becoming Canada’s dominant pot company. And it has succeeded, building up everything from production to its own finished products — complete with slick branding — and even rolling out its own retail presence in provinces that allow private ownership of marijuana shops.

It’s little wonder why the stock has become the go-to name in the sector. It’s the biggest, and bulls argue it’s the best run as well.

One thing I like best about the company is that CEO Bruce Linton and his management team always have their foot on the gas pedal. Canopy is relentlessly growing, investing cash almost as fast as they can raise it. One recent investment saw the company commit $500 million towards hemp production in Idaho — facilities that can easily be converted to growing marijuana once it becomes legal across the U.S. Bulls say this is only a matter of time.

Let’s take a closer look at Canopy’s performance over the last five years and just how much money an investor would have made if they put a mere $10,000 into the company back then. You won’t believe the results.

Canada’s top stock

No other stock on the TSX has done better than Canopy Growth over the last five years.

Back in 2014, the company wasn’t much more than a few employees, a tiny market cap, and a bold idea. Some investors saw the long-term potential in medical marijuana, but few saw just how close we were to legalizing the drug.

Liberal party leader Justin Trudeau pledged to legalize cannabis if his party was elected in 2015, but many investors saw this as an empty election promise designed to get younger voters excited about a Liberal government. Trudeau easily defeated incumbent Prime Minister Stephen Harper and the legalization plan was put in motion.

We’ve also seen a remarkable shift in attitude about cannabis over the last few years. Folks staunchly opposed to legalization have softened their stance. Formerly secret users are more open about their habit. You’re often greeted with the pungent smell of marijuana when walking down a busy Canadian street nowadays.

And Canopy Growth investors have been the major beneficiaries of this trend.

On June 6, 2014, Canopy Growth shares were worth a mere $2.75 each. As I type this, the stock is trading for $53.80. This translates into a massive 1,891% return.

It’s even more striking when you look at the annual return. Canopy Growth has compounded investor money by more than 89% each year since 2014. That’s enough to turn a $10,000 investment into one worth $199,087.

It would take an investor earning 10% a year approximately 30 years to turn $10,000 into $200,000. It took Canopy Growth investors just five years.

Can Canopy do it again?

The short answer is no. Canopy cannot grow another 1,891% in the next five years. It is simply too big today.

But that doesn’t mean it’s a poor investment choice today. The stock could easily double or triple between now and 2024. That would still be a pretty satisfactory result.

As bulls have argued for years, the legal pot market is really just getting started. And Canopy is in a great position to benefit from that. Patient investors should do well on the stock. Just maybe not as well as before.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nelson Smith has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »